#Gilead Sciences

Ninety-seven percent of those who took the Gilead regimen after failing a previous therapy were cured in a recent study.

The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

A study in Glasgow provided treatment to those receiving opioid substitution therapy for opioid addiction.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.

The drugmaker is accused of infringing on a patent held by rival Merck & Co. over its formulas for Sovaldi and Harvoni treatment.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

In early research in cell cultures and mice, scientists found Sovaldi could possibly thwart Zika’s harmful effects on unborn babies.

A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC